Search Results
Crizotinib
Crizotinib is FDA approved for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Limitations of Use: The safety and efficacy of Xalkori have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.
Nivolumab
Nivolumab is FDA approved for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Nelarabine
Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.
Reflecting on a Year of Accomplishments and Looking Forward to 2017
LLS President and CEO Louis J. DeGennaro shares his optimism about LLS’s role and promise for patients.
The Fruits of Our Funding
Advances in cancer research seem to be occurring at dizzying speed these days.
Targeted Therapy focus of LLS-hosted Symposium at ASH
As researchers gain greater understanding of how cancer works, they are becoming more adept at developing precisely targeted therapies that go after the tumor cells while sparing the healthy cells.
Today The Leukemia & Lymphoma Society (LLS) kicked off the 57th American Society of Hematology (ASH) Annual Meeting in Orlando with a satellite symposium entitled, “Molecularly Targeted Therapies for Hematologic Malignancies.”
LLS Aligns with “Moonshot” Goal of Putting Patients at the Center of Cancer Care
The national “Moonshot” initiative is repeatedly making news headlines as the $1 billion effort designed to eliminate cancer has groundbreaking potential. Led by Vice President Joe Biden, the effort is focused on accelerating research and making more therapies available – and blood cancer patients have much to gain.
I recently joined an expert panel at the annual Milken Institute Global Conference, “Promise of the Cancer Moonshot,” to share The Leukemia & Lymphoma Society’s (LLS) perspective about what needs to be done to move this effort forward.
#ASH15 Day 4: Breakthrough Therapy Designation for Novel Immunotherapy
Yesterday we learned the exciting news that the FDA has granted Breakthrough Therapy designation for an investigational immunotherapy LLS is supporting through our Therapy Acceleration Program (TAP).
An integrated liquid biopsy framework for surveillance of residual disease and host immune status of T-cell lymphomas
I aim to develop an accurate disease monitoring system and identify immunologic determinants of development and progression in T-cell lymphoma (TCL). I will integrate noninvasive liquid biopsy methods by high-throughput sequencing. I will study blood samples at various milestones, including pre-diagnostic, diagnostic/baseline, and post-treatment specimens during the natural history of TCL. Using these novel tools and unique specimens, my goal is the development of effective therapies for TCL.Moving Cancer to the Back Burner
I am glad to be here. Literally.
Being a survivor is a good thing. I could have been six feet under, after being diagnosed with acute lymphoblastic leukemia (ALL) on December 16, 2000. I was 40 years old, raising two children with my husband Ron. Our daughter was almost 4 years old and our son was 16 months.
Burlington Stores Surpasses $3 Million Goal to Help Fight Blood Cancer
Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) 14th consecutive year of partnership in the fight against blood cancers was a huge success. As LLS’s #1 national corporate partner and honored friend, Burlington, the national off-price retailer, beat its $3 million goal for its annual Light The Night Walk campaign by a long shot, raising an astonishing $3.35 million. This marks one of the retailer’s most successful and longest running philanthropic campaigns.
Asparaginase erwinia chrysanthemi (recombinant)- rywn
Rylaze™ is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Venetoclax
Venetoclax is FDA approved
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Ifosfamide
Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.
Belinostat
Belinostat is FDA approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Cladribine
Cladribine is FDA approved to treat people who have active hairy cell leukemia. It is also used to treat some other types of leukemia and lymphoma.
Mosunetuzumab-axgb
Mosunetuzumab-axgb is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
A phase 1/2 study of IMT-009, an antibody targeting CD161, in patients with advanced solid tumors or lymphomas
In August 2021, LLS made an equity investment in Immunitas Therapeutics to support the "Phase 1 Clinical Development of IMT-009, an Antibody Targeting CD161, in Patients With Advanced Solid Tumors or Lymphomas."Renewed focus on a national initiative to cure cancer
For more than 66 years The Leukemia & Lymphoma Society (LLS) has dedicated its energy and resources to finding cures for blood cancers, investing more than $1 billion over that time. Last night in his State of the Union address, President Obama appointed Vice President Joe Biden to take the lead in a “moon shot” mission to cure cancer. We at LLS agree the time is right.
“It’s personal for everybody,” the Vice President later said in a statement.
Is a Clinical Trial Right For You?
Because it can take up to 15 years for a new blood cancer drug to be studied and made available for doctors to prescribe, some patients opt for clinical trials as a way to gain early access to a promising treatment. Advancing new cancer therapies requires years of extensive clinical investigation, but clinical trials come with no guarantees. "A drug is allowed to enter the clinical trial phase based on scientific evidence including cell and animal studies, but it's still considered experimental and unproven.